ERCC1 and ovarian carcinoma: DNA damage or DNA repair defects caused by BRCA or ERCC1 mutations can also activate this pathway and thereby potentiate PARP inhibitor effects in ERCC1-deficient nonsmall cell lung cancer, BRCA1-deficient TNBC, and ovarian cancer (Ding et al. 2018; Chabanon et al. 2019).